SYRA (Syra Health) Piotroski F-Score: 6 (As of Jul. 08, 2026) — 20% Above Median


SYRA Syra Health Corp SYRA
12 GF Score
Price $0.70
GF Value $0.23
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Syra Health Piotroski F-Score?

Syra Health SYRA -3.81% 12 Piotroski F-Score is 6 as of Jul. 08, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 649 Healthcare Providers & Services companies, Syra Health ranks better than 75.04% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Syra Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Syra Health's Piotroski F-Score or its related term are showing as below:

SYRA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 6 years, the highest Piotroski F-Score of Syra Health was 6. The lowest was 3. And the median was 5.

Syra Health  (OTCPK:SYRA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Syra Health Piotroski F-Score Related Terms


Syra Health Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Syra Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syra Health Piotroski F-Score Chart

Syra Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 6.00 3.00 5.00

Syra Health Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 4.00 5.00 6.00

SYRA vs NIVF, BICX, HLYK: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, Syra Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syra Health Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Syra Health's Piotroski F-Score falls into.


SYRA
12GF Score
Syra Health Corp SYRA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.064 + -0.226 + -0.135 + 0.241 = $-0.18 Mil.
Cash Flow from Operations was -0.072 + -0.244 + -0.289 + 1.362 = $0.76 Mil.
Revenue was 1.946 + 1.688 + 1.734 + 2.274 = $7.64 Mil.
Gross Profit was 0.753 + 0.555 + 0.591 + 0.971 = $2.87 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3.723 + 3.471 + 3.263 + 2.773 + 3.945) / 5 = $3.435 Mil.
Total Assets at the begining of this year (Mar25) was $3.72 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $3.93 Mil.
Total Current Liabilities was $1.58 Mil.
Net Income was -1.39 + -0.418 + -0.504 + -0.472 = $-2.78 Mil.

Revenue was 1.97 + 2.253 + 2.007 + 1.858 = $8.09 Mil.
Gross Profit was 0.35 + 0.668 + 0.335 + 0.589 = $1.94 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(4.552 + 3.238 + 4.425 + 3.679 + 3.723) / 5 = $3.9234 Mil.
Total Assets at the begining of last year (Mar24) was $4.55 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $3.65 Mil.
Total Current Liabilities was $1.27 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Syra Health's current Net Income (TTM) was -0.18. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Syra Health's current Cash Flow from Operations (TTM) was 0.76. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-0.184/3.723
=-0.04942251

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-2.784/4.552
=-0.6115993

Syra Health's return on assets of this year was -0.04942251. Syra Health's return on assets of last year was -0.6115993. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Syra Health's current Net Income (TTM) was -0.18. Syra Health's current Cash Flow from Operations (TTM) was 0.76. ==> 0.76 > -0.18 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/3.435
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/3.9234
=0

Syra Health's gearing of this year was 0. Syra Health's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3.928/1.582
=2.482933

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3.647/1.266
=2.8807267

Syra Health's current ratio of this year was 2.482933. Syra Health's current ratio of last year was 2.8807267. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Syra Health's number of shares in issue this year was 12.781. Syra Health's number of shares in issue last year was 11.587. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.87/7.642
=0.37555614

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.942/8.088
=0.2401088

Syra Health's gross margin of this year was 0.37555614. Syra Health's gross margin of last year was 0.2401088. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=7.642/3.723
=2.05264572

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=8.088/4.552
=1.77680141

Syra Health's asset turnover of this year was 2.05264572. Syra Health's asset turnover of last year was 1.77680141. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Syra Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Syra Health (SYRA) has a Piotroski F-Score of 6 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Syra Health and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Syra Health's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Syra Health ranks #162 out of 649 companies in the Healthcare Providers & Services industry, placing it in the top 25%.
Is Syra Health's Piotroski F-Score too high?
Syra Health's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Syra Health's value of 6 is 20% above this industry median. Based on the distribution chart, Syra Health ranks #162 out of 649 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's Piotroski F-Score compare to NIVF and BICX?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #162 out of 649 companies for Piotroski F-Score. This places Syra Health in the top 25% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Syra Health's value of 6 is 20% above this benchmark. Historically, Syra Health's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Syra Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 649 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syra Health's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Syra Health and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $0.70 — trading 205.2% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Healthcare Providers & Services industry median of 5.00. Syra Health's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Syra Health (SYRA), the current Piotroski F-Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syra Health (SYRA) Overvalued in 2026?

Based on GuruFocus' analysis, Syra Health stock appears to be overvalued. The current stock price of $0.70 is trading 205.2% above its estimated GF Value™ of $0.23. GuruFocus considers Syra Health to be Significantly Overvalued.

Key valuation signals for SYRA:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: $0.23 vs. price of $0.70 (205.2% above fair value)
  • GF Score™: 12/100 with 5 warning signs
  • Industry Position: 20% above the Healthcare Providers & Services median (#162 of 649)

No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Syra Health Business Description

Address 1119 Keystone Way North, No. 201, Carmel, IN, USA, 46032
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score

Get the complete analysis for SYRA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$0.23
GF Value